Clinical Trials Logo

Clinical Trial Summary

This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Demonstrate whether carbon ion therapy provides improved patient reported health related quality of life (PRO-HRQOL) outcomes and less significant toxicities compared with surgery. II. Demonstrate whether carbon ion therapy provides improved local control versus proton therapy. OUTLINE: Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05033288
Study type Observational
Source Mayo Clinic
Contact
Status Not yet recruiting
Phase
Start date August 30, 2021
Completion date August 30, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Not yet recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Active, not recruiting NCT03595228 - BN Brachyury and Radiation in Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Recruiting NCT02986516 - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease N/A
Active, not recruiting NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Recruiting NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Phase 1
Recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2
Completed NCT00713037 - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas N/A
Completed NCT00592748 - Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine Phase 1/Phase 2
Recruiting NCT04429542 - Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Phase 1
Recruiting NCT01182779 - Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base Phase 3
Active, not recruiting NCT00349024 - Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer N/A